Patiromer Treats Hyperkalemia in Diabetic Kidney Disease

This article originally appeared here.
Share this content:
Patiromer Treats Hyperkalemia in Diabetic Kidney Disease
Patiromer Treats Hyperkalemia in Diabetic Kidney Disease

(HealthDay News) -- A new drug, patiromer, decreases serum potassium levels in patients with hyperkalemia and diabetic kidney disease, according to the results of a phase 2 study published in the July 14 issue of the Journal of the American Medical Association.

George Bakris, M.D., a professor of medicine at the University of Chicago, and colleagues randomly assigned 306 patients with type 2 diabetes and high potassium levels to one of three doses of patiromer twice a day for a month. Patients also took renin-angiotensin-aldosterone system inhibitors before and during the trial.

The researchers found that all doses of patiromer significantly reduced potassium levels after a month and continued to keep levels low over a year. And for most patients, potassium levels remained low without falling below normal. Over the course of a year, 5.6 percent of patients developed hypokalemia; 7.2 percent developed hypomagnesemia and 6.3 percent experienced mild to moderate constipation.

If patiromer is approved by the U.S. Food and Drug Administration, the author of an accompanying journal editorial urges the agency to consider requiring post-marketing studies. These should assess whether the drug slows kidney disease progression, reduces the need for dialysis, and improves heart failure outcomes, Wolfgang Winkelmayer, M.D., Sc.D., chair of nephrology at Baylor College of Medicine in Houston, said in the editorial.

The current study was funded by Relypsa, the maker of patiromer.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Improved achievement of glycemic targets, reduced body weight

European, American Guidelines Lead to Different Recs for Statins

European, American Guidelines Lead to Different Recs for ...

Quantification of CAC score can improve stratification for those at high, low risk for events

Hyperbaric O2 Therapy Effective in Maxillary Osteoradionecrosis

Hyperbaric O<sub>2</sub> Therapy Effective in Maxillary Osteoradionecrosis

Positive clinical outcome with HBOT for 85.7 percent of patients with maxillary bone osteoradionecrosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »